Skip to main content
. Author manuscript; available in PMC: 2016 May 16.
Published in final edited form as: Leukemia. 2015 May 14;29(10):1981–1992. doi: 10.1038/leu.2015.106

Figure 2.

Figure 2

MLN4924 treatment reduces miR-155 expression in FLT3-ITD AML cell lines and primary patient blasts. (a) AML cell lines: FLT3-ITD carrying MOLM-13 and wt FLT3 expressing THP-1, Kasumi-1 and CG-SH were cultured in the presence of indicated concentrations of MLN4924, or vehicle control (DMSO) for 12 h and the expression of miR-155 was determined by the TaqMan assay and normalized to U44 levels. (b) Mature miR-155 expression was analyzed by the TaqMan method in MV4-11 cells, following 12 h of treatment with MLN4924 at the indicated concentrations. The results were normalized to U44. On the basis of triplicate readings of an average of three separate experiments, the average relative fold change was calculated in comparison with the vehicle controls, which were set to 1. (c) Time course of MV4-11 treatment with 300 nm MLN4924. (d) TaqMan assay of miR-155 expression in FLT3-ITD AML primary patient blasts treated with MLN4924 for 12 h. Results are shown as relative fold change after normalization with U44 and 2 Ct, based on triplicate readings of an average of three readings in the same experiments.